JMB-HEADER RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2022  1,200
2021  1,540
2020  1,374
2019  1,023
2018  0,932
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 47(2013) N 3 p. 321-342;
A.V. Bruter*, A.V. Avdeev, A.V. Belyavsky

Regulated Expression Systems for Gene Therapy

Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia

*aleabruter@gmail.com
Received - 2012-10-10; Accepted - 2013-10-01

Gene therapy is a promising and rapidly developing field of modern medicine and is expected to improve or even cure the diseases that are incurable with classical therapies. The logics of the development of gene therapy in the nearest future will require the systems wherein a regulation is possible for expression of therapeutic genes. The review considers the currently available regulated gene therapeutic systems, which can be divided into two main classes. One includes the systems wherein external inducers are used to trigger therapeutic gene expression. Systems of the other class are autoregulated and function without an external inducer. The most important first-class expression systems are based on the regulation by tetracycline, rapamycin derivative-induced dimerization, steroid hormones, regulatory RNAs, and physical factors. The most important systems of the second class are regulated by oxygen or glucose levels.

gene therapy, gene expression, regulated systems, tetracycline-dependent systems, dimerization inducers, rapamycin-dependent systems, nuclear hormones, hypoxia-inducible systems, glucose-regulated systems



JMB-FOOTER RAS-JOURNALS